-
"Xingguang Yiyi-In-Depth Interpretation" Season 2 Online Conference-Jiangsu, Anhui and Zhejiang Special
Time of Update: 2021-10-20
focuses on immunotherapy, is committed to cure cancer patients, 22 June 2021, Fosun Kate CAR-T cell therapy drugs Yi Kaida ® ® (A Jilun game Injection) in the country Officially approved in 38 countries and regions, nearly 5,000 patients used an overall response rate (ORR) of 83%, a complete response (CR) rate of 58%, and a median overall survival (OS) of 25.
-
In China, 1 million people have lost their anus due to bowel cancer... Doctors are not immune
Time of Update: 2021-10-20
At present, the total number of patients with intestinal stoma in China due to colorectal tumors or trauma, ulcerative colitis , Crohn's disease and other reasons has exceeded 1 million, and it is still increasing at a rate of 100,000 per year .
-
Front Oncol: Treatment outcome of patients with extensive-stage small cell lung cancer (ED-SCLC): retrospective analysis of 9994 patients from South Korea
Time of Update: 2021-10-20
In summary, the retrospective study of the large Korean population showed that the IP regimen can significantly improve the OS and TFST of patients with ED-SCLC in the first-line treatment .
-
The first domestic "dual immunity" therapy was approved!
Time of Update: 2021-10-20
Immunization FundProfessor Lu Shun, Director of the Oncology Department of the Thoracic Hospital Affiliated to Shanghai Jiaotong University, said: “ Malignant pleural mesothelioma is a highly aggressive and rare cancer with limited treatment options and a 5- year survival rate of less than 10% .
-
"Xingguang Yiyi-In-Depth Interpretation" Online Conference-Guangdong, Fujian and Jiangxi Special Session
Time of Update: 2021-10-20
CAR-T lymphoma immune June 22, 2021, Fosun Kate CAR-T cell therapy drugs Yi Kaida ® ® (A Jilun game Injection) in the country officially approved 38 countries and regions, nearly 5 000 cases Patient useThe overall response rate (ORR) was 83%, the complete response (CR) rate was 58%, the median overall survival (OS) was 25.
-
Cyberknife target delineation for early non-small cell lung cancer
Time of Update: 2021-10-20
Preparation for CT localization of non-small cell lung cancer A gold label was placed in the lesion 1 week before the patient was positioned .
4. Examples of non-small cell lung cancer: delineation of target areas and organs at risk4.
-
16 exquisite pictures: delineation of the radiotherapy target area for locally advanced non-small cell lung cancer
Time of Update: 2021-10-20
Basic InformationDiagnosis : Poorly differentiated adenocarcinoma of the upper lobe of the right lung, stage IIIA .
Radiotherapy target area: right upper lobe mass, right hilar, mediastinal 2R, 3A, 4R, 7 lymph node drainage area .
Target delineation map of tumor precision radiotherapy [M].
-
A new breakthrough in the treatment of KRAS G12C mutant cancers, a new combination of KRAS inhibitors shows positive results
Time of Update: 2021-10-20
Test drugs in Phase Ib CodeBreaK 101 studyA branch of the Phase Ib CodeBreaK 101 study-evaluating Lumakras in combination with afatinib-recruited 33 patients with KRAS G12C mutant non-small cell lung cancer ( NSCLC ) who had undergone a large number of previous treatments , including 5 patients who had previously received Lumakras monotherapy .
-
Front Oncol: Efficacy of induction chemotherapy combined with intensity-modulated radiotherapy (IMRT) in the treatment of patients with simultaneous metastatic nasopharyngeal carcinoma
Time of Update: 2021-10-20
Recently, Frontiers in Oncology published the results of a study completed by the Shanghai Fudan University team, mainly to evaluate the efficacy and impact of induction chemotherapy + intensity-modulated radiotherapy (IMRT) in patients with nasopharyngeal carcinoma initially diagnosed with distant metastasis Prognostic factors .
-
Imfinzi combined with tremelimumab in the treatment of liver cancer, phase III trial shows that it can improve overall survival
Time of Update: 2021-10-20
AstraZeneca's drug combination Imfinzi combined with tremelimumab has been shown to significantly improve the overall survival of patients with first-line unresectable liver cancer .
Infection of non-alcoholic fatty liverHCC is the most common type of liver cancer, the third leading cause of cancer deaths, and the sixth most common cancer in the world .
-
Clin Cancer Res: The efficacy of anti-colony stimulating factor monoclonal antibody Lacnotuzumab combined with gemcitabine-carboplatin in the treatment of triple-negative breast cancer
Time of Update: 2021-10-20
Lacnotuzumab (Lacnotuzumab, an anti-colony stimulating factor monoclonal antibody)Female patients with advanced TNBC who have high levels of tumor-associated macrophages and are not suitable for surgery or radiotherapy were recruited and randomly divided into two groups to receive gemcitabine-carboplatin + latuzumab (10 mg/kg·3 weeks) or gemcitabine-carbohydrate Platinum treatment .
-
J Immunother Cancer: First-line BRAF-MEKi resistance in patients with melanoma brain metastases (MBMs) is poorly treated with ipilimumab-nivolumab
Time of Update: 2021-10-20
Studies have shown that after first-line BRAF-MEKi progresses in patients with melanoma brain metastases (MBMs), the second-line ipilimumab-nivolumab treatment effect is poor .
Studies have shown that after first-line BRAF-MEKi progresses in patients with melanoma brain metastases (MBMs), the second-line ipilimumab-nivolumab treatment effect is poor .
-
Clin Cancer Res: Long-term follow-up results of the Phase 3 coBRIM study of Verofenib + Pabocinil in the treatment of BRAFV600+ advanced melanoma
Time of Update: 2021-10-20
Patients with normal baseline lactate dehydrogenase levels and low tumor burden and patients with complete remission had the longest OS and PFSIn summary, the results of the extended follow-up of the coBRIM study confirmed that compared with veilofenib alone, veilofenib combined with pabocinib can bring long-term clinical benefits to patients with advanced melanoma who are BRAF V600 mutation-positive .
-
For the treatment of chronic lymphocytic leukemia, the bispecific γδ T cell binding antibody LAVA-051 obtained FDA orphan drug certification
Time of Update: 2021-10-20
Monoclonal B lymphocytes in peripheral bloodLAVA-051 is a bispecific antibody that preferentially activates Gamma Delta T cells and type 1 natural killer T (NKT) cells to recruit the immune system to attack CD1d-expressing cancer cells .
-
J Clin Oncol: A randomized trial by Professor Ming Shi's team from Sun Yat-sen University Cancer Hospital confirmed that the use of FOLFOX for hepatic arterial infusion chemotherapy can significantly prolong the survival of patients with unresectable large liver cancer!
Time of Update: 2021-10-20
In a previous phase II clinical trial, the use of fluorouracil, leucovorin, and oxaliplatin (FOLFOX) for hepatic artery infusion chemotherapy (HAIC) resulted in greater than transarterial chemoembolization (TACE) in unresectable large hepatocellular carcinoma.
-
J Thorac Oncol: RNA deep sequencing shows that fusion heterogeneity can predict the therapeutic effect of crizotinib on ALK rearranged non-small cell lung cancer
Time of Update: 2021-10-20
ALK rearrangement of non-small cell lung cancer ( NSCLC ) gene fusion variants may predict the prognosis of patients, but the results of previous studies are still uncertain .
-
J Urol: In patients undergoing robotic partial nephrectomy, what are the consequences of taking aspirin during the perioperative period?
Time of Update: 2021-10-20
The use of aspirin during the perioperative period during RPN is reasonable and safe, however, there is a higher risk of blood transfusion and major complications .
-
The British Medicines and Healthcare Products Regulatory Agency (MHRA) supports Merck's MET inhibitor Teppetko in the treatment of non-small cell lung cancer (NSCLC)
Time of Update: 2021-10-20
1 months; 66 patients in the liquid biopsy group The ORR rate was 48% (95% CI, 36 to 61); the ORR rate of 60 patients in the tissue biopsy group was 50% (95% CI, 37 to 63); the response rate assessed by the researchers was 56% (95% CI , 45 to 66), regardless of the previous treatment for advanced or metastatic disease, the remission rate is similar (Figure 1) .
-
Young man, why suddenly "cancer"?
Time of Update: 2021-10-20
Among people aged 20 to 39, thyroid cancer increases by 3% every year .
Among people aged 20 to 39, thyroid cancer increases by 3% every year .
-
Front Oncol: Efficacy of salvage surgery for patients with recurrent nasopharyngeal carcinoma: a meta-analysis
Time of Update: 2021-10-20
The meta-analysis showed that salvage surgery for patients with recurrent nasopharyngeal cancer is beneficial to survival .
The meta-analysis showed that salvage surgery for patients with recurrent nasopharyngeal cancer is beneficial to survival .
